Chapter/Section Purchase

Leave This Empty:

Gene Editing Technology Market, Global Outlook and Forecast 2023-2030

Choose Chapter/Section to Purchase

List of Chapters/Sections(Table Of Content)
1 Introduction to Research & Analysis Reports
1.1 Gene Editing Technology Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Editing Technology Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Editing Technology Overall Market Size
2.1 Global Gene Editing Technology Market Size: 2023 VS 2030
2.2 Global Gene Editing Technology Market Size, Prospects & Forecasts: 2023-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Key Gene Editing Technology Players in Global Market
3.2 Global Companies Gene Editing Technology Product & Technology
4 Gene Editing Technology Companies Profiles
4.1 Thermo Fisher Scientific
4.1.1 Thermo Fisher Scientific Company Summary
4.1.2 Thermo Fisher Scientific Business Overview
4.1.3 Thermo Fisher Scientific Gene Editing Technology Product Offerings & Technology
4.1.4 Thermo Fisher Scientific Gene Editing Technology R&D, and Plans
4.2 SIGMA ALDRICH
4.2.1 SIGMA ALDRICH Company Summary
4.2.2 SIGMA ALDRICH Business Overview
4.2.3 SIGMA ALDRICH Gene Editing Technology Product Offerings & Technology
4.2.4 SIGMA ALDRICH Gene Editing Technology R&D, and Plans
4.3 Dharmacon
4.3.1 Dharmacon Company Summary
4.3.2 Dharmacon Business Overview
4.3.3 Dharmacon Gene Editing Technology Product Offerings & Technology
4.3.4 Dharmacon Gene Editing Technology R&D, and Plans
4.4 Cellectics
4.4.1 Cellectics Company Summary
4.4.2 Cellectics Business Overview
4.4.3 Cellectics Gene Editing Technology Product Offerings & Technology
4.4.4 Cellectics Gene Editing Technology R&D, and Plans
4.5 CRISPR Therapeutics
4.5.1 CRISPR Therapeutics Company Summary
4.5.2 CRISPR Therapeutics Business Overview
4.5.3 CRISPR Therapeutics Gene Editing Technology Product Offerings & Technology
4.5.4 CRISPR Therapeutics Gene Editing Technology R&D, and Plans
4.6 AstraZeneca
4.6.1 AstraZeneca Company Summary
4.6.2 AstraZeneca Business Overview
4.6.3 AstraZeneca Gene Editing Technology Product Offerings & Technology
4.6.4 AstraZeneca Gene Editing Technology R&D, and Plans
4.7 Bio Rad
4.7.1 Bio Rad Company Summary
4.7.2 Bio Rad Business Overview
4.7.3 Bio Rad Gene Editing Technology Product Offerings & Technology
4.7.4 Bio Rad Gene Editing Technology R&D, and Plans
4.8 Allele Biotech
4.8.1 Allele Biotech Company Summary
4.8.2 Allele Biotech Business Overview
4.8.3 Allele Biotech Gene Editing Technology Product Offerings & Technology
4.8.4 Allele Biotech Gene Editing Technology R&D, and Plans
4.9 Recombinetics
4.9.1 Recombinetics Company Summary
4.9.2 Recombinetics Business Overview
4.9.3 Recombinetics Gene Editing Technology Product Offerings & Technology
4.9.4 Recombinetics Gene Editing Technology R&D, and Plans
4.10 Lonza
4.10.1 Lonza Company Summary
4.10.2 Lonza Business Overview
4.10.3 Lonza Gene Editing Technology Product Offerings & Technology
4.10.4 Lonza Gene Editing Technology R&D, and Plans
4.11 GE Healthcare
4.11.1 GE Healthcare Company Summary
4.11.2 GE Healthcare Business Overview
4.11.3 GE Healthcare Gene Editing Technology Product Offerings & Technology
4.11.4 GE Healthcare Gene Editing Technology R&D, and Plans
4.12 Editas Medicine
4.12.1 Editas Medicine Company Summary
4.12.2 Editas Medicine Business Overview
4.12.3 Editas Medicine Gene Editing Technology Product Offerings & Technology
4.12.4 Editas Medicine Gene Editing Technology R&D, and Plans
4.13 Agilent Technologies
4.13.1 Agilent Technologies Company Summary
4.13.2 Agilent Technologies Business Overview
4.13.3 Agilent Technologies Gene Editing Technology Product Offerings & Technology
4.13.4 Agilent Technologies Gene Editing Technology R&D, and Plans
4.14 QIAGEN NV
4.14.1 QIAGEN NV Company Summary
4.14.2 QIAGEN NV Business Overview
4.14.3 QIAGEN NV Gene Editing Technology Product Offerings & Technology
4.14.4 QIAGEN NV Gene Editing Technology R&D, and Plans
5 Sights by Region
5.1 By Region - Global Gene Editing Technology Market Size, 2024 & 2030
5.2 By Region - Global Gene Editing Technology Revenue, (2024-2030)
5.3 United States
5.3.1 Key Players of Gene Editing Technology in United States
5.3.2 United States Gene Editing Technology Development Current Situation and Forecast
5.4 Europe
5.4.1 Key Players of Gene Editing Technology in Europe
5.4.2 Europe Gene Editing Technology Development Current Situation and Forecast
5.5 China
5.5.1 Key Players of Gene Editing Technology in China
5.5.2 China Gene Editing Technology Development Current Situation and Forecast
5.6 Rest of World
6 Sights by Product
6.1 By Type - Global Gene Editing Technology Market Size Markets, 2024 & 2030
6.2 Homologous Recombination
6.3 Meganuclease
7 Sights by Application
7.1 By Application - Global Gene Editing Technology Market Size, 2024 & 2030
7.2 Agriculture
7.3 Medical
7.4 Other
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer